Endometrial cancer patients and tibolone: A matched case-control study

Maturitas

Volumn 55, Issue 3, 2006, Pages 264-269

  Lee, Kwang Beom ^a   Lee, Jong Min ^b   Lee, Jae Kwan ^c   Cho, Chi Heum ^d  

^a Gachon University   (South Korea)

^b Kyung Hee University   (South Korea)

^c Korea University   (South Korea)

^d Keimyung University   (South Korea)

Author keywords

Endometrial cancer patients; Survival; Tibolone

Indexed keywords

TIBOLONE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG USE; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PROGNOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NORPREGNENES; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33748710040     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.03.012     Document Type: Article

References (30)

1. 2002 Annual report of the Korea central cancer registry (2002.1-2002.12). Republic of Korea: Korea Central Cancer Registry, Ministry of Health and Welfare; 2003.
2. Annual report of gynecologic cancer registry program in Korean for 2002 (Jan. 1st, 2002-Dec. 31st, 2002). Kr J Obstet Gynecol 2004; 6:1029-71.
3. Gitsch G., Hanzal E., Jensen D., and Hacker N.F. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 85 (1995) 504-508
4. Chapman J.A., DiSaia P.J., Osann K., Roth P.D., Gillotte D.L., and Berman M.L. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175 (1996) 1195-1200
5. American College of Obstetricians Gynecologists. ACOG committee opinion-hormone replacement therapy in women treated for endometrial cancer. Int J Gynaecol Obstet 73 (2001) 283-284
6. Parslov M., Lidegaard O., Klintorp S., et al. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 182 (2000) 23-29
7. Tran B.N., Connell P.P., Waggoner S., Rotmensch J., and Mundt A.J. Characteristics and outcome of endometrial carcinoma patients age 45 years and younger. Am J Clin Oncol 23 (2000) 476-480
8. Evans-Metcalf E.R., Brooks S.E., Reale F.R., and Baker S.P. Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 91 (1998) 349-354
9. Feldman B.M., Voda A., and Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res Nurs Health 8 (1985) 261-268
10. Hreshchyshyn M.M., Hopkins A., Zylstra S., and Anbar M. Effects of natural menopause, hysterectomy, and oophorectomy on lumbar spine and femoral neck bone densities. Obstet Gynecol 72 (1988) 631-638
11. Centerwall B.S. Premenopausal hysterectomy and cardiovascular disease. Am J Obstet Gynecol 139 (1981) 58-61
12. SEER Cancer Statistics Review 1975-2000. (http://seer.cancer.gov/csr/1975_2000).
13. Creasman W.T., Odicino F., Maisonneuve P., et al. Carcinoma of the corpus uteri. J Epidemiol Biostat 6 (2001) 47-86
14. North American Menopause Society (NAMS) 2003. Estrogen and progesterone use in the peri-and postmenopausal women: September 2003 position statement of the North American Menopause Society. Menopause 2003; 10:497-506.
15. Creasman W.T., Henderson D., Hinshaw W., and Clarke-Pearson D.L. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67 (1986) 326-330
16. Lee R.B., Burke T., and Park R.C. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36 (1990) 189-191
17. Chapman J.A., Disaia P.J., Osann K., Roth P.D., Gillotte D.L., and Berman M.L. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 175 (1996) 1195-1200
18. Suriano K.A., McHale M., McLaren C.E., Li K.T., Re A., and DiSaia P.J. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol 97 (2001) 555-560
19. DiSaia P.J., and Brewster W.R. Hormone replacement therapy for survivors of breast and endometrial cancer. Curr Oncol Rep 4 (2002) 152-158
20. Kenemans P., and Speroff L. Tibolone: clinical recommendations and practical guidelines a report of the International Tibolone Consensus Group. Maturitas 51 (2005) 21-28
21. Baracat E.C., Barbosa I.C., Giordano M.G., et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 5 (2002) 60-69
22. Morris E.P., Wilson P.O.G., Robinson J., and Rymer J.M. Long-term effects of tibolone on the genital tract in postmenopausal women. Br J Obstet Gynaecol 106 (1999) 954-959
23. Davis S.R. The effects of tibolone on mood and libido. Menopause 9 (2002) 162-170
24. Egarter Ch, Huber J., Leikermoser R., et al. Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints. Maturitas 23 (1996) 35-48
25. Roux C., Pelissier C., Fechtenbaum J., Loiseau-Peres S., and Benhamou C.L. Randomized, double-blind, 2-year comparison of tibolone with 17β-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos Int 13 (2002) 241-248
26. Lundström E., Christow A., Svane G., et al. Effects of tibolone and a continous combined HRT regimen on mammographic breast density. Am J Obstet Gynecol 186 (2002) 717-722
27. Valdivia I., Campodonico I., Tapia A., et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 81 (2004) 617-623
28. Blok L.J., De Ruiter P.E., Kuhne E.C., et al. Progestogenic effects of tibolone on human endometrial cancer cells. J Clin Endocrinol Metab 88 (2003) 2327-2334
29. Hanifi-Moghaddam P., Gielen S.C., Kloosterboer H.J., et al. Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone. J Clin Endocrinol Metab 90 (2005) 973-983
30. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365 (2005) 1543-1551